SCHEMBL26078527

SCHEMBL26078527

Cc1c(CC2=NCCN2)cc(Cl)c2c1ccn2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1D P28221 8/20 0.44
▸ HTR1B P28222 7/20 0.44
▸ ADRA2A P08913 5/20 0.43
▸ ADRA1A P35348 4/20 0.43
▸ ADRA2B P18089 4/20 0.43
▸ ADRA2C P18825 4/20 0.43
▸ ADRA1D P25100 3/20 0.43
▸ ADRA1B P35368 3/20 0.43
▸ TAAR1 Q96RJ0 5/20 0.43
▸ MAPK1 P28482 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HTR1A P08908 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ NISCH Q9Y2I1 1/20 0.40
▸ CFB P00751 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26078535 0.81 HTR1D (0.41) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078536 0.76 HTR1D (0.41) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078524 0.76 CFB (0.57) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078368 0.75 HTR1D (0.45) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078522 0.73 HTR1D (0.46) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078540 0.73 HTR1D (0.43) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078511 0.70 TAAR1 (0.65) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078539 0.68 HTR1D (0.45) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078507 0.67 HTR1D (0.57) HTR1DHTR1BADRA2AADRA1AADRA2B
SCHEMBL26078452 0.67 HTR1D (0.68) HTR1DHTR1BADRA2AADRA1AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE ADRA1A, ADRB1, ADRA1D HTR1D 47/4885HTR1B 105/4885ADRA2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback